<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
FHTX
Foghorn Therapeutics
$
()


  • Foghorn Therapeutics appoints Humer as Chief Financial Officer

    4/16/2024 - 07:09am
  • Foghorn Therapeutics expects cash runway into first half of 2026

    3/7/2024 - 07:03am
  • Foghorn Therapeutics reports FY23 EPS ($2.34), consensus ($2.48)

    3/7/2024 - 07:03am
  • Foghorn Therapeutics, Eli Lilly to present new preclinical data at AACR

    3/5/2024 - 17:03pm
  • Foghorn Therapeutics says Lilly selects FHD-909 for clinical development

    2/8/2024 - 07:11am
  • Foghorn Therapeutics announces strategic objectives for 2024

    1/8/2024 - 07:43am
  • Prime Medicine appoints Reine as Chief Financial Officer

    1/5/2024 - 08:07am
  • Foghorn Therapeutics CFO Allan Reine to depart

    1/3/2024 - 16:06pm
  • Foghorn Therapeutics expects cash to fund operations into 1H26

    11/2/2023 - 07:02am
  • Foghorn Therapeutics reports Q3 EPS (34c), consensus (75c)

    11/2/2023 - 07:02am
  • Foghorn doses first patient in Phase 1 combination study of FHD-286

    8/31/2023 - 07:02am
  • Foghorn Therapeutics appoints Quintas-Cardama as Chief Medical Officer

    8/8/2023 - 07:44am
  • Foghorn Therapeutics reports Q2 EPS (70c), consensus (73c)

    8/4/2023 - 07:06am
  • Foghorn Therapeutics price target lowered to $19 from $21 at Goldman Sachs

    6/28/2023 - 17:46pm
  • Foghorn FHD-286 discontinuation a net positive, says H.C. Wainwright

    6/28/2023 - 11:33am
dynamic_feed Breaking News